Context: Fibrogenesis imperfecta ossium (FIO) is a rare bone disease manifested by generalized bone pain, fragility fractures, progressive disability, and extensive mineralization defect seen in bone biopsy specimens. The pathogenesis of the disease is unknown and currently there is no effective treatment.
F ibrogenesis imperfecta ossium (FIO), first described in 1950 (1) , is a very rare, adult-onset, presumably acquired, relentlessly progressive, crippling, and ultimately fatal bone disease. Age of onset of FIO is usually between the third and sixth decade, and is almost always insidious. The lag time between the onset of skeletal symptoms and the diagnosis varies from 2 to 10 years (2, 3) , and most patients are bed bound at the time of diagnosis (4) . Clinically, FIO manifests with generalized bone pain and multiple fractures involving both the axial and the appendicular skeleton (5) .
Except for an elevated serum alkaline phosphatase (AP) level, routine biochemical measurements are normal in patients with FIO (6) (7) (8) . In advanced disease, radiographs show a distinctive "fishnet appearance" (9) and Looser zones (5) . Bone histological examination shows extensive mineralization defect simulating osteomalacia. However, unlike all other osteomalacic conditions (10) , bone collagen in FIO is not birefringent on polarized microscopy, and transmission electron microscopy (TEM) shows disorganized collagen fibrils; both are characteristic features of FIO (11) . The radiological features of FIO are present in the entire skeleton except the skull (12) , and have a characteristic "beheaded" appearance on a total-body bone scan (i.e., superscan without uptake in the skull). At the onset of the disease, osteopenia with a prominent trabecular pattern is seen. As the disease progresses, there is marked reduction in bone density, with loss of trabeculae and coarsening of the remaining trabeculae along the lines of stress, giving the typical fishnet appearance (12) , most markedly in the weight-bearing bones (i.e., vertebrae and femur).
The basic abnormality in FIO appears to be an acquired defect in bone collagen fibrillary arrangement rather than in its structure (13) . Although no mutations in type I collagen genes have been reported in FIO, a genetic basis cannot be excluded, because father-todaughter transmission has been reported (2). Pathogenesis of FIO still remains elusive and no effective therapy currently exists.
Several therapeutic strategies, based primarily on either bone histology or presence of paraproteinemia, including vitamin D, melphalan, steroids, plasmapheresis, bisphosphonate, calcitonin, testosterone and dihydrotestosterone, have been tried with variable success (3, 4, 12) . Growth hormone (GH) has been used with some success to treat osteoporosis (14) and promote linear growth in patients with X-linked hypophosphatemic osteomalacia (15) . These well-known osteo-anabolic effects of recombinant human growth hormone (rhGH) (14-16) prompted us to consider rhGH therapy in two brothers with FIO.
Patient 1
A 48-year-old Asian Indian man presented with a 10-year history of generalized bone pain, multiple fractures, and muscle weakness. His symptoms had progressively worsened over the last 2 years to the extent that he was unable to perform even the minimal activities of daily living, and he finally became bedridden. Family history suggested a similar skeletal disorder in his mother, a maternal uncle, and younger brother (patient 2). Both his mother and maternal uncle died of their disabling bone disease.
On examination, the patient was bedridden and unable to walk. He weighed 47 kg; an accurate height could not be determined because of his inability to stand. His body habitus was normal without apparent short stature. Blood pressure was 120/80 mm Hg, pulse rate was 82/min, respiratory rate was 16/min, and temperature was normal. He had generalized bone tenderness with proximal muscle weakness. He did not have blue sclera, deafness, or dental abnormalities. The remainder of the physical examination was unremarkable.
Complete blood cell count, erythrocyte sedimentation rate, serum protein electrophoresis, screening for celiac sprue, arterial pH, and thyroid, adrenal, gonadal, and pituitary function tests were normal. His comprehensive biochemical profile was normal except for an elevated serum AP level (Table 1) . Skeletal survey revealed a normal skull, rugger-jersey appearance of the lumbar spine, pseudofracture of the right scapula [ Fig. 1(a) ], multiple rib fractures, bilateral coxa vara, and femoral neck fractures with a fishnet appearance (Supplemental Fig. 1) . Ultrasonography of the neck and abdomen was normal. Bone mineral density (BMD) of the spine by dualenergy x-ray absorptiometry was low, with a Z-score of 22.2 standard deviations (BMD, 0.812 g/cm 2 ). Whole-body bone scan showed increased radiotracer uptake in the shoulders, elbows, wrists, and small joints of the hands, as well as in the right scapula at the site of pseudofracture, multiple ribs, entire spine, and distal ends of tibiae, but without any uptake in the skull. The characteristic beheaded appearance seen only in FIO [ Fig. 1(c) ]. In vivo double tetracycline-labeled transiliac bone biopsy specimen (undecalcified) showed thickened bony trabeculae with extensive wide and scattered osteoidlike areas simulating osteomalacia [ Fig. 1(e) ]. There was loss of birefringence under polarized microscopy, suggesting abnormal collagen arrangement [ Fig. 1(g) ].
Patient 2
This 38-year-old younger brother of patient 1 had an almost identical history as his brother, with backache and generalized bone pain of 6 to 8 years' duration. One year before presentation, he sustained a fracture of the right femoral neck with dislocation. Subsequently, he sustained fractures of the shafts of the left humerus and left femur, with resultant skeletal deformities (i.e., right hip dislocation with flexion deformities at both knees and postfracture deformity at the shaft of the left humerus). These progressively worsened, leading to a bedridden status at the age of 37 years. He had no history of tooth loss, deafness, or muscle weakness. He had been taking calcium and vitamin D supplements and analgesics for bone pain for the past 2 to 3 years without relief.
On examination, he was bedridden and unable to stand because of generalized bone tenderness and contractures at both knee joints. His weight was 37 kg, blood pressure was 120/80 mm Hg, pulse rate was 78/min, and respiratory rate was 15/min. His inability to stand and bilateral knee contractures precluded an accurate height measurement. Like his brother, he did not have blue sclera or deafness, and dentition was normal. The remainder of the physical examination was normal.
Complete blood cell count, erythrocyte sedimentation rate, serum protein electrophoresis, screening for celiac sprue, arterial pH, and the relevant endocrine function tests were all normal, as was his comprehensive biochemical profile except for elevated serum AP level (Table 1) . Skeletal survey showed a normal skull, bilateral femoral neck and left humeral shaft fractures [ Fig. 2(a) ], and pseudofracture in the left fibula. BMD of the spine was low, with a Z-score of 22.5 standard deviations (BMD, 0.640 g/cm 2 ). Results of a whole-body bone scan were suggestive of a superscan without uptake in the skull [ Fig. 2(c)] . A transiliac bone biopsy (undecalcified) after in vivo double tetracycline labeling confirmed severe mineralization defects simulating osteomalacia, with extensive osteoid accumulation, areas of sclerosis, resorption areas at edges of bone, and foci of new bone formation [ Fig. 2(e) ]. Polarized microscopy revealed loss of collagen birefringence [ Fig. 2(g) ] and TEM showed disorganized collagen fibrils [Supplemental Fig. 2(a) ].
Materials and Methods
The study was conducted at the Postgraduate Institute of Medical Education and Research, Chandigarh, India, after the patients gave informed written consent. The diagnosis of FIO was established by the clinical features supported by radiological findings (i.e., Looser zone) and characteristic bone scan findings (superscan without uptake in the skull, referred to as "beheaded scan"). Mineralization defects simulating osteomalacia were confirmed by bone histomorphometry (6).
Laboratory methods
A complete blood cell count and a comprehensive biochemical profile, which included total calcium, phosphate, creatinine, AP, total protein, and albumin levels; and urine calcium, phosphate, and creatinine levels were measured in the hospital laboratory by standard methods (AutoAnalyzer Modular P 800; Roche Diagnostics, Indianapolis, IN). Serum calcium was adjusted for albumin. Serum intact parathyroid hormone and 25-hydroxyvitamin D levels were measured by chemiluminiscent assay (ELECSYS-2010; Roche Diagnostics).
Bone histomorphometry
Pre-and posttreatment transiliac bone biopsies after in vivo double tetracycline labeling, and bone histomorphometry were performed, as previously reported (17, 18) 
Response to rhGH therapy
Both siblings were already being treated with oral calcium (500 mg twice per day) and vitamin D (cholecalciferol, 60,000 IU/mo) for more than 2 years without any satisfactory improvement when they were referred to us. We started treatment with rhGH 1 IU/d subcutaneously at bedtime. In view of normal GH response to insulin-induced hypoglycemia in both the patients, rhGH was prescribed in osteoanabolic doses. Along with rhGH therapy, calcium and vitamin D supplementation were continued at the same doses. Response to rhGH treatment was assessed at regular intervals, with clinical and biochemical measurements every 3 months and by radiological imaging every 6 months. Bone histology was reassessed at the end of 1 year of rhGH therapy. Both patients were closely monitored for rhGH-related adverse effects.
Results
Both patients began to notice symptomatic improvement within 3 months of rhGH therapy, with further clinical improvement by the end of 1 year. Bone pain resolved in both patients sufficiently to perform most of the activities of daily living. Except for the elevated serum AP level, all biochemical measurements were normal at baseline and remained so throughout follow-up. The serum AP level declined gradually in both patients, reaching near normal by 1 year, and remained so at 2 years (80 and 209 U/L for patients 1 and 2, respectively). All fractures healed Evaluation of initial bone biopsy specimens showed extensive mineralization defect simulating osteomalacia [ Fig. 1 (e) and 2(e)] without any tetracycline labels. Specimens from repeated bone biopsies showed a dramatic improvement in mineralization, with reductions in osteoid volume/bone volume fraction from 90.1% to 33.7% and 76.6% to 37.5% in patients 1 and 2, respectively, after rhGH treatment, with only scanty single tetracycline labels. There was the expected increase in mineralized bone [Figs. 1(f) and 2(f)], and restoration of collagen birefringence [Figs. 1(h) and 2(h)].
In patient 2, TEM showed an organized collagen fibrillary pattern [Supplemental Fig. 2(b) ]. Because of the chaotic nature of the pretreatment biopsies, we could not perform conventional histomorphometry. Finally, both patients were screened for mutations in the COL1A1 and COL1A2 genes but found none. Neither patient developed rhGH treatmentrelated adverse effects over the treatment period of 1 year.
Discussion
We describe two siblings with FIO who were treated successfully with rhGH, which we believe is a novel form of therapy, with clinical, biochemical, radiological, and bone histomorphometrical improvement. Involvement of the two brothers in this report and the presumed FIO in their mother and a maternal uncle (both died before reaching a definitive diagnosis) favors a genetic etiology.
Because of consistently elevated serum AP levels in FIO, a few cases have initially been diagnosed as Paget disease of bone. However, the imaging studies (i.e., radiographs and bone scan) in our patients were not consistent with this diagnosis (19) . Axial osteomalacia (AOM), another skeletal disorder resembling FIO, is also characterized by bone pain and elevated serum AP levels, but the radionuclide uptake in AOM is confined to the axial skeleton in contrast to the generalized increased uptake in FIO (except the skull). Both patients had diffuse skeletal involvement with the classical beheaded activity pattern, excluding AOM in our patients (7) . A diffuse polyclonal or monoclonal gammopathy has been reported in 30% to 50% of patients (19) . Although neither of our patients had gammopathy, both had elevated serum AP levels that normalized after rhGH treatment.
Almost all attempted treatments to date were based either on normalizing the mineralization defect (resembling osteomalacia) with vitamin D or its metabolites (7), or with melphalan and steroids or plasmapheresis when there was evidence of monoclonal gammopathy. Bisphosphonate, calcitonin, testosterone, and dihydrotestosterone have been tried in a few cases (4), but almost all treatments tried thus far have been either partially effective or unsatisfactory (4, 19) . Drugs that inhibit bone resorption and/or stimulate bone formation could theoretically be useful, but in the presence of an extensive mineralization defect, bisphosphonates and recombinant human parathyroid hormone may not be effective, and perhaps may even make the disease process worse. Furthermore, a previous attempt to treat the condition with bisphosphonates was ineffective (4).
We treated our patients with rhGH because it is anabolic to bone (14, 16) . GH and insulin-like growth factor -1 (IGF-1) receptors are present on osteoblasts. GH action on bone is mediated through IGF-1. Initially, GH therapy results in bone resorption, which is followed by bone formation (20) .GH stimulates osteoblast to secrete collagenous and noncollagenous proteins (osteocalcin, osteopontin, and osteonectin) (16) , which are important for collagen matrix organization and its subsequent mineralization (21, 22) . After interacting with IGF-1 receptor, IGF-1 activates the phosphatidyl inositol 3-kinase/AKT-Runx2 signaling pathway. In turn, Runx2 regulates expression of different genes, including col1, AP, osteopontin, osteonectin, and osteocalcin, which mediate osteoblast differentiation (23) . Studies have reported that mice lacking RUNX2 are devoid of osteoblasts and produce cartilaginous skeleton that is devoid of mineralized matrix (24) . In our patients, the collagen fibril arrangement was markedly improved. There are several studies in which rhGH was used safely as an anabolic agent to bone. Valimaki et al. (25) reported improvement in BMD in GH-deficient adults after treatment with rhGH for 42 weeks. Gilberg et al. (26) used rhGH in men with idiopathic osteoporosis and showed improvement in BMD. In a 10-year follow-up study, Krantz et al. (14) demonstrated efficacy in reducing fracture rate and increasing BMD, and safety of rhGH in postmenopausal osteoporosis. In a prospective study, Marini et al. (27) used rhGH in patients with osteogenesis imperfecta. There was accelerated growth velocity, increased bone formation rate, and increased bone density in GH-treated individuals after 1 year of rhGH therapy (27) . Hence, rhGH has safely been used long term to treat various metabolic bone and other disorders. We propose that rhGH was effective in our patients because of GH-mediated RUNX2-dependent induction of collagenous and noncollagenous protein synthesis, which may play an important role in the matrix organization and, as a result, subsequent mineralization. To the best of our knowledge, this is the first report on the use of rhGH therapy in FIO with successful results.
Our study is limited by the experience only in these two brothers with FIO and it lacks genetic and confirmatory studies to confirm our mechanistic hypothesis that rhGH changes collagen fibrillary arrangement. Isolation and culture of osteoblasts and study of their response to rhGH in vitro may provide clues to the pathogenesis of FIO. Like all other treatment strategies, it is too early to predict long-term outcome, but the initial response to rhGH therapy is very encouraging and could be used long term, based on the experience in other disease states. We propose that rhGH is a potential therapy for FIO, for which no effective therapy currently exists.
